aa change |
Molecular test |
6142508 |
Optional |
additional pathology findings |
Pathology detail |
--- |
Optional |
adrenal hormone |
Diagnosis |
C2264 |
Optional |
adverse event grade |
Follow up |
2944515 |
Optional |
adverse event |
Follow up |
3125302 |
Optional |
age at diagnosis |
Diagnosis |
3225640 |
Required |
age at index |
Demographic |
6028530 |
Optional |
age at last exposure |
Exposure |
--- |
Optional |
age at onset |
Exposure |
--- |
Optional |
age is obfuscated |
Demographic |
--- |
Optional |
aids risk factors |
Follow up |
--- |
Optional |
ajcc clinical m |
Diagnosis |
3440331 |
Optional |
ajcc clinical n |
Diagnosis |
3440330 |
Optional |
ajcc clinical stage |
Diagnosis |
3440332 |
Optional |
ajcc clinical t |
Diagnosis |
3440328 |
Optional |
ajcc pathologic m |
Diagnosis |
3045439 |
Optional |
ajcc pathologic n |
Diagnosis |
3203106 |
Optional |
ajcc pathologic stage |
Diagnosis |
3203222 |
Optional |
ajcc pathologic t |
Diagnosis |
3045435 |
Optional |
ajcc staging system edition |
Diagnosis |
2722309 |
Optional |
alcohol days per week |
Exposure |
3114013 |
Optional |
alcohol drinks per day |
Exposure |
3124961 |
Optional |
alcohol frequency |
Exposure |
--- |
Optional |
alcohol history |
Exposure |
2201918 |
Optional |
alcohol intensity |
Exposure |
3457767 |
Optional |
alcohol type |
Exposure |
--- |
Optional |
anaplasia present type |
Pathology detail |
4925534 |
Optional |
anaplasia present |
Pathology detail |
6059599 |
Optional |
aneuploidy |
Molecular test |
C2873 |
Optional |
ann arbor b symptoms described |
Diagnosis |
--- |
Optional |
ann arbor b symptoms |
Diagnosis |
2902402 |
Optional |
ann arbor clinical stage |
Diagnosis |
5615604 |
Optional |
ann arbor extranodal involvement |
Diagnosis |
3364582 |
Optional |
ann arbor pathologic stage |
Diagnosis |
5615605 |
Optional |
antigen |
Molecular test |
6142523 |
Optional |
asbestos exposure type |
Exposure |
--- |
Optional |
asbestos exposure |
Exposure |
1253 |
Optional |
barretts esophagus goblet cells present |
Follow up |
3440216 |
Optional |
best overall response |
Diagnosis |
2003324 |
Optional |
biospecimen type |
Molecular test |
--- |
Optional |
biospecimen volume |
Molecular test |
--- |
Optional |
blood test normal range lower |
Molecular test |
6142571 |
Optional |
blood test normal range upper |
Molecular test |
6142535 |
Optional |
bmi |
Follow up |
2006410 |
Optional |
body surface area |
Follow up |
653 |
Optional |
bone marrow malignant cells |
Pathology detail |
--- |
Optional |
breslow thickness |
Pathology detail |
64809 |
Optional |
burkitt lymphoma clinical variant |
Diagnosis |
3770421 |
Optional |
cancer detection method |
Diagnosis |
--- |
Optional |
cause of death source |
Demographic |
--- |
Optional |
cause of death |
Demographic |
2554674 |
Optional |
cause of response |
Follow up |
6161025 |
Optional |
cd4 count |
Follow up |
4182751 |
Optional |
cdc hiv risk factors |
Follow up |
--- |
Optional |
cell count |
Molecular test |
6142528 |
Optional |
chemical exposure type |
Exposure |
C36290 |
Optional |
chemo concurrent to radiation |
Treatment |
--- |
Optional |
child pugh classification |
Diagnosis |
2931791 |
Optional |
chromosomal translocation |
Molecular test |
C3420 |
Optional |
chromosome arm |
Molecular test |
C13355 |
Optional |
chromosome |
Molecular test |
6142404 |
Optional |
cigarettes per day |
Exposure |
2001716 |
Optional |
circumferential resection margin |
Pathology detail |
6161030 |
Optional |
classification of tumor |
Diagnosis |
3288124 |
Optional |
clinical trial indicator |
Treatment |
--- |
Optional |
clonality |
Molecular test |
--- |
Optional |
coal dust exposure |
Exposure |
--- |
Optional |
cog liver stage |
Diagnosis |
6013618 |
Optional |
cog neuroblastoma risk group |
Diagnosis |
4616452 |
Optional |
cog renal stage |
Diagnosis |
6013641 |
Optional |
cog rhabdomyosarcoma risk group |
Diagnosis |
6133604 |
Optional |
columnar mucosa present |
Pathology detail |
--- |
Optional |
comorbidities |
Follow up |
2970715 |
Optional |
comorbidity method of diagnosis |
Follow up |
6142386 |
Optional |
comorbidity |
Follow up |
2970715 |
Optional |
consistent pathology review |
Pathology detail |
--- |
Optional |
copy number |
Molecular test |
6142519 |
Optional |
country of residence at enrollment |
Demographic |
7050286 |
Optional |
course number |
Treatment |
C166235 |
Optional |
cytoband |
Molecular test |
6142405 |
Optional |
days to adverse event |
Follow up |
6154728 |
Optional |
days to best overall response |
Diagnosis |
6154732 |
Optional |
days to birth |
Demographic |
6154723 |
Optional |
days to comorbidity |
Follow up |
--- |
Optional |
days to death |
Demographic |
6154724 |
Optional |
days to diagnosis |
Diagnosis |
6154733 |
Optional |
days to first event |
Follow up |
--- |
Optional |
days to follow up |
Follow up |
6154727 |
Required |
days to imaging |
Follow up |
--- |
Optional |
days to last follow up |
Diagnosis |
3008273 |
Optional |
days to last known disease status |
Diagnosis |
3008273 |
Optional |
days to progression free |
Follow up |
--- |
Optional |
days to progression |
Follow up |
6154730 |
Optional |
days to recurrence |
Diagnosis |
6154731 |
Optional |
days to recurrence |
Follow up |
6154731 |
Optional |
days to risk factor |
Follow up |
--- |
Optional |
days to test |
Molecular test |
--- |
Optional |
days to treatment end |
Treatment |
6154725 |
Optional |
days to treatment start |
Treatment |
6154726 |
Optional |
diabetes treatment type |
Follow up |
3587247 |
Optional |
diagnosis is primary disease |
Diagnosis |
--- |
Required |
disease response |
Follow up |
5750671 |
Optional |
dlco ref predictive percent |
Follow up |
2180255 |
Optional |
double expressor lymphoma |
Diagnosis |
C138900 |
Optional |
double hit lymphoma |
Diagnosis |
C125904 |
Optional |
drug category |
Treatment |
--- |
Optional |
dysplasia degree |
Pathology detail |
--- |
Optional |
dysplasia type |
Pathology detail |
--- |
Optional |
ecog performance status |
Follow up |
88 |
Optional |
eln risk classification |
Diagnosis |
--- |
Optional |
embolic agent |
Treatment |
C97229 |
Optional |
enneking msts grade |
Diagnosis |
6003955 |
Optional |
enneking msts metastasis |
Diagnosis |
6003958 |
Optional |
enneking msts stage |
Diagnosis |
6060045 |
Optional |
enneking msts tumor site |
Diagnosis |
6003957 |
Optional |
environmental tobacco smoke exposure |
Exposure |
--- |
Optional |
esophageal columnar dysplasia degree |
Diagnosis |
3440917 |
Optional |
esophageal columnar metaplasia present |
Diagnosis |
3440218 |
Optional |
ethnicity |
Demographic |
2192217 |
Required |
evidence of progression type |
Follow up |
--- |
Optional |
evidence of recurrence type |
Follow up |
--- |
Optional |
exon |
Molecular test |
6142411 |
Optional |
exposure duration years |
Exposure |
C83280 |
Optional |
exposure duration |
Exposure |
--- |
Optional |
exposure source |
Exposure |
--- |
Optional |
exposure type |
Exposure |
--- |
Optional |
extracapsular extension |
Pathology detail |
C25502 |
Optional |
extranodal extension |
Pathology detail |
C117309 |
Optional |
extrascleral extension |
Pathology detail |
C111028 |
Optional |
eye color |
Follow up |
C157437 |
Optional |
fab morphology code |
Diagnosis |
C91220 |
Optional |
fev1 fvc post bronch percent |
Follow up |
3302956 |
Optional |
fev1 fvc pre bronch percent |
Follow up |
3302955 |
Optional |
fev1 ref post bronch percent |
Follow up |
3302948 |
Optional |
fev1 ref pre bronch percent |
Follow up |
3302947 |
Optional |
figo stage |
Diagnosis |
3225684 |
Optional |
figo staging edition year |
Diagnosis |
--- |
Optional |
first event |
Follow up |
--- |
Optional |
first symptom prior to diagnosis |
Diagnosis |
6133605 |
Optional |
gastric esophageal junction involvement |
Diagnosis |
6059632 |
Optional |
gender |
Demographic |
2200604 |
Required |
gene symbol |
Molecular test |
6142392 |
Required |
gleason grade group |
Diagnosis |
5918370 |
Optional |
gleason grade tertiary |
Diagnosis |
--- |
Optional |
gleason patterns percent |
Diagnosis |
--- |
Optional |
gleason score |
Diagnosis |
C28084 |
Optional |
goblet cells columnar mucosa present |
Diagnosis |
3440219 |
Optional |
greatest tumor dimension |
Pathology detail |
--- |
Optional |
gross tumor weight |
Pathology detail |
6133606 |
Optional |
haart treatment indicator |
Follow up |
--- |
Optional |
height |
Follow up |
649 |
Optional |
hepatitis sustained virological response |
Follow up |
6423783 |
Optional |
histone family |
Molecular test |
6142511 |
Optional |
histone variant |
Molecular test |
6142515 |
Optional |
history of tumor type |
Follow up |
--- |
Optional |
history of tumor |
Follow up |
--- |
Optional |
hiv viral load |
Follow up |
2649682 |
Optional |
hormonal contraceptive type |
Follow up |
--- |
Optional |
hormonal contraceptive use |
Follow up |
--- |
Optional |
hormone replacement therapy type |
Follow up |
--- |
Optional |
hpv positive type |
Follow up |
2922649 |
Optional |
hpv strain |
Molecular test |
--- |
Optional |
hysterectomy margins involved |
Follow up |
--- |
Optional |
hysterectomy type |
Follow up |
--- |
Optional |
icd 10 code |
Diagnosis |
3226287 |
Optional |
igcccg stage |
Diagnosis |
--- |
Optional |
imaging anatomic site |
Follow up |
C13717 |
Optional |
imaging findings |
Follow up |
--- |
Optional |
imaging result |
Follow up |
--- |
Optional |
imaging suv max |
Follow up |
C69310 |
Optional |
imaging suv |
Follow up |
C69310 |
Optional |
imaging type |
Follow up |
--- |
Optional |
immunosuppressive treatment type |
Follow up |
--- |
Optional |
initial disease status |
Treatment |
--- |
Optional |
inpc grade |
Diagnosis |
6133602 |
Optional |
inpc histologic group |
Diagnosis |
4616372 |
Optional |
inrg stage |
Diagnosis |
5777238 |
Optional |
inss stage |
Diagnosis |
6133603 |
Optional |
international prognostic index |
Diagnosis |
2500234 |
Optional |
intron |
Molecular test |
6514355 |
Optional |
irs group |
Diagnosis |
6141658 |
Optional |
irs stage |
Diagnosis |
5162089 |
Optional |
ishak fibrosis score |
Diagnosis |
3182621 |
Optional |
iss stage |
Diagnosis |
2465385 |
Optional |
karnofsky performance status |
Follow up |
2003853 |
Optional |
laboratory test |
Molecular test |
--- |
Optional |
largest extrapelvic peritoneal focus |
Pathology detail |
6690680 |
Optional |
last known disease status |
Diagnosis |
5424231 |
Optional |
laterality |
Diagnosis |
827 |
Optional |
lesions treated number |
Treatment |
--- |
Optional |
loci abnormal count |
Molecular test |
6074182 |
Optional |
loci count |
Molecular test |
6074183 |
Optional |
locus |
Molecular test |
C45822 |
Optional |
lymph node dissection method |
Pathology detail |
--- |
Optional |
lymph node dissection site |
Pathology detail |
--- |
Optional |
lymph node involved site |
Pathology detail |
--- |
Optional |
lymph node involvement |
Pathology detail |
--- |
Optional |
lymph nodes positive |
Pathology detail |
89 |
Optional |
lymph nodes removed |
Pathology detail |
--- |
Optional |
lymph nodes tested |
Pathology detail |
3 |
Optional |
lymphatic invasion present |
Pathology detail |
64171 |
Optional |
margin distance |
Diagnosis |
--- |
Optional |
margin status |
Pathology detail |
--- |
Optional |
margins involved site |
Diagnosis |
--- |
Optional |
masaoka stage |
Diagnosis |
3952848 |
Optional |
max tumor bulk site |
Diagnosis |
--- |
Optional |
medulloblastoma molecular classification |
Diagnosis |
6002209 |
Optional |
menopause status |
Follow up |
2434914 |
Optional |
metaplasia present |
Pathology detail |
--- |
Optional |
metastasis at diagnosis site |
Diagnosis |
3029815 |
Optional |
metastasis at diagnosis |
Diagnosis |
6133614 |
Optional |
method of diagnosis |
Diagnosis |
6161031 |
Optional |
micropapillary features |
Diagnosis |
6068784 |
Optional |
mismatch repair mutation |
Molecular test |
6142534 |
Optional |
mitosis karyorrhexis index |
Diagnosis |
4616412 |
Optional |
mitotic count |
Diagnosis |
C47864 |
Optional |
mitotic count |
Molecular test |
C47864 |
Optional |
mitotic total area |
Molecular test |
--- |
Optional |
molecular analysis method |
Molecular test |
6142401 |
Required |
molecular consequence |
Molecular test |
6142403 |
Optional |
morphologic architectural pattern |
Pathology detail |
--- |
Optional |
morphology |
Diagnosis |
3226275 |
Required |
mutation codon |
Molecular test |
--- |
Optional |
nadir cd4 count |
Follow up |
--- |
Optional |
necrosis percent |
Pathology detail |
--- |
Optional |
necrosis present |
Pathology detail |
--- |
Optional |
non nodal regional disease |
Pathology detail |
--- |
Optional |
non nodal tumor deposits |
Pathology detail |
3107051 |
Optional |
number of cycles |
Treatment |
--- |
Optional |
number of fractions |
Treatment |
--- |
Optional |
number proliferating cells |
Pathology detail |
5432636 |
Optional |
occupation duration years |
Demographic |
2435424 |
Optional |
occupation duration years |
Exposure |
2435424 |
Optional |
occupation type |
Exposure |
C25193 |
Optional |
ovarian specimen status |
Diagnosis |
6690671 |
Optional |
ovarian surface involvement |
Diagnosis |
6690674 |
Optional |
pack years smoked |
Exposure |
2955385 |
Optional |
pancreatitis onset year |
Follow up |
3457763 |
Optional |
papillary renal cell type |
Diagnosis |
--- |
Optional |
parent with radiation exposure |
Exposure |
--- |
Optional |
pathogenicity |
Molecular test |
--- |
Optional |
pediatric kidney staging |
Diagnosis |
--- |
Optional |
percent tumor invasion |
Pathology detail |
--- |
Optional |
percent tumor nuclei |
Pathology detail |
2841225 |
Optional |
perineural invasion present |
Pathology detail |
64181 |
Optional |
peripancreatic lymph nodes positive |
Pathology detail |
5983082 |
Optional |
peripancreatic lymph nodes tested |
Pathology detail |
6050944 |
Optional |
peritoneal fluid cytological status |
Diagnosis |
6690681 |
Optional |
peritoneal washing results |
Follow up |
C159340 |
Optional |
ploidy |
Molecular test |
6142527 |
Optional |
pregnancy count |
Follow up |
--- |
Optional |
pregnancy outcome |
Follow up |
--- |
Optional |
pregnant at diagnosis |
Diagnosis |
--- |
Optional |
premature at birth |
Demographic |
6010765 |
Optional |
prescribed dose |
Treatment |
--- |
Optional |
primary diagnosis |
Diagnosis |
6161032 |
Required |
primary disease |
Diagnosis |
--- |
Optional |
primary gleason grade |
Diagnosis |
5936800 |
Optional |
prior malignancy |
Diagnosis |
3382736 |
Optional |
prior treatment |
Diagnosis |
4231463 |
Optional |
procedures performed |
Follow up |
--- |
Optional |
progression or recurrence anatomic site |
Follow up |
6161026 |
Optional |
progression or recurrence type |
Follow up |
6142385 |
Optional |
progression or recurrence |
Diagnosis |
3121376 |
Optional |
progression or recurrence |
Follow up |
3121376 |
Optional |
prostatic chips positive count |
Pathology detail |
--- |
Optional |
prostatic chips total count |
Pathology detail |
--- |
Optional |
prostatic involvement percent |
Pathology detail |
--- |
Optional |
protocol identifier |
Treatment |
C132299 |
Optional |
race |
Demographic |
2192199 |
Required |
radon exposure |
Exposure |
2816352 |
Optional |
reason treatment ended |
Treatment |
--- |
Optional |
recist targeted regions number |
Follow up |
--- |
Optional |
recist targeted regions sum |
Follow up |
--- |
Optional |
reflux treatment type |
Follow up |
3440206 |
Optional |
regimen or line of therapy |
Treatment |
6161024 |
Optional |
relationship age at diagnosis |
Family history |
5300571 |
Optional |
relationship gender |
Family history |
6161021 |
Optional |
relationship primary diagnosis |
Family history |
6161022 |
Optional |
relationship type |
Family history |
2690165 |
Optional |
relative with cancer history |
Family history |
6161023 |
Optional |
relatives with cancer history count |
Family history |
--- |
Optional |
residual disease |
Diagnosis |
C4809 |
Optional |
residual disease |
Treatment |
C4809 |
Optional |
residual tumor measurement |
Pathology detail |
--- |
Optional |
residual tumor |
Pathology detail |
C4809 |
Optional |
respirable crystalline silica exposure |
Exposure |
--- |
Optional |
rhabdoid percent |
Pathology detail |
6790120 |
Optional |
rhabdoid present |
Pathology detail |
--- |
Optional |
risk factor method of diagnosis |
Follow up |
C177576 |
Optional |
risk factor treatment |
Follow up |
6514356 |
Optional |
risk factor |
Follow up |
6142389 |
Optional |
risk factors |
Follow up |
6142389 |
Optional |
route of administration |
Treatment |
C38114 |
Optional |
sarcomatoid percent |
Pathology detail |
2429786 |
Optional |
sarcomatoid present |
Pathology detail |
--- |
Optional |
satellite nodule present |
Diagnosis |
--- |
Optional |
scan tracer used |
Follow up |
--- |
Optional |
second exon |
Molecular test |
--- |
Optional |
second gene symbol |
Molecular test |
6142393 |
Optional |
secondary gleason grade |
Diagnosis |
5936802 |
Optional |
secondhand smoke as child |
Exposure |
6841888 |
Optional |
site of resection or biopsy |
Diagnosis |
6161034 |
Required |
sites of involvement count |
Diagnosis |
--- |
Optional |
sites of involvement |
Diagnosis |
--- |
Optional |
size extraocular nodule |
Pathology detail |
--- |
Optional |
smoking frequency |
Exposure |
--- |
Optional |
specialized molecular test |
Molecular test |
6142526 |
Optional |
supratentorial localization |
Diagnosis |
3133891 |
Optional |
synchronous malignancy |
Diagnosis |
6142390 |
Optional |
test analyte type |
Molecular test |
6142394 |
Optional |
test result |
Molecular test |
6142397 |
Required |
test units |
Molecular test |
6142525 |
Optional |
test value range |
Molecular test |
--- |
Optional |
test value |
Molecular test |
6142524 |
Optional |
therapeutic agents |
Treatment |
2975232 |
Optional |
therapeutic level achieved |
Treatment |
--- |
Optional |
therapeutic target level |
Treatment |
--- |
Optional |
time between waking and first smoke |
Exposure |
3279220 |
Optional |
timepoint category |
Follow up |
C68568 |
Optional |
timepoint category |
Molecular test |
C68568 |
Optional |
timepoint category |
Treatment |
C68568 |
Optional |
tissue or organ of origin |
Diagnosis |
6161035 |
Required |
tobacco smoking onset year |
Exposure |
2228604 |
Optional |
tobacco smoking quit year |
Exposure |
2228610 |
Optional |
tobacco smoking status |
Exposure |
2181650 |
Optional |
transcript |
Molecular test |
6142465 |
Optional |
transglottic extension |
Pathology detail |
--- |
Optional |
treatment anatomic site |
Treatment |
5615611 |
Optional |
treatment arm |
Treatment |
7068995 |
Optional |
treatment dose max |
Treatment |
--- |
Optional |
treatment dose units |
Treatment |
--- |
Optional |
treatment dose |
Treatment |
2182728 |
Optional |
treatment duration |
Treatment |
--- |
Optional |
treatment effect indicator |
Treatment |
--- |
Optional |
treatment effect |
Treatment |
6514354 |
Optional |
treatment frequency |
Treatment |
--- |
Optional |
treatment intent type |
Treatment |
2793511 |
Optional |
treatment or therapy |
Treatment |
4231463 |
Optional |
treatment outcome duration |
Treatment |
--- |
Optional |
treatment outcome |
Treatment |
5102383 |
Optional |
treatment type |
Treatment |
5102381 |
Optional |
tumor confined to organ of origin |
Diagnosis |
4925494 |
Optional |
tumor depth |
Diagnosis |
--- |
Optional |
tumor focality |
Diagnosis |
3174022 |
Optional |
tumor grade category |
Diagnosis |
--- |
Optional |
tumor grade |
Diagnosis |
2785839 |
Optional |
tumor largest dimension diameter |
Pathology detail |
64215 |
Optional |
tumor level prostate |
Pathology detail |
--- |
Optional |
tumor regression grade |
Diagnosis |
6471217 |
Optional |
tumor thickness |
Pathology detail |
C176286 |
Optional |
type of smoke exposure |
Exposure |
--- |
Optional |
type of tobacco used |
Exposure |
--- |
Optional |
uicc clinical m |
Diagnosis |
--- |
Optional |
uicc clinical n |
Diagnosis |
--- |
Optional |
uicc clinical stage |
Diagnosis |
--- |
Optional |
uicc clinical t |
Diagnosis |
--- |
Optional |
uicc pathologic m |
Diagnosis |
--- |
Optional |
uicc pathologic n |
Diagnosis |
--- |
Optional |
uicc pathologic stage |
Diagnosis |
--- |
Optional |
uicc pathologic t |
Diagnosis |
--- |
Optional |
uicc staging system edition |
Diagnosis |
--- |
Optional |
undescended testis corrected age |
Follow up |
--- |
Optional |
undescended testis corrected laterality |
Follow up |
--- |
Optional |
undescended testis corrected method |
Follow up |
--- |
Optional |
undescended testis corrected |
Follow up |
--- |
Optional |
undescended testis history laterality |
Follow up |
--- |
Optional |
undescended testis history |
Follow up |
C12326 |
Optional |
use per day |
Exposure |
--- |
Optional |
variant origin |
Molecular test |
--- |
Optional |
variant type |
Molecular test |
6142402 |
Optional |
vascular invasion present |
Pathology detail |
64358 |
Optional |
vascular invasion type |
Pathology detail |
3168001 |
Optional |
viral hepatitis serologies |
Follow up |
4395982 |
Optional |
vital status |
Demographic |
5 |
Required |
weeks gestation at birth |
Demographic |
2737369 |
Optional |
weight |
Follow up |
651 |
Optional |
weiss assessment findings |
Diagnosis |
C104015 |
Optional |
weiss assessment score |
Diagnosis |
3648744 |
Optional |
who cns grade |
Diagnosis |
--- |
Optional |
who nte grade |
Diagnosis |
--- |
Optional |
wilms tumor histologic subtype |
Diagnosis |
4358735 |
Optional |
year of birth |
Demographic |
2896954 |
Optional |
year of death |
Demographic |
2897030 |
Optional |
year of diagnosis |
Diagnosis |
2896960 |
Optional |
year of follow up |
Follow up |
--- |
Optional |
years smoked |
Exposure |
3137957 |
Optional |
zone of origin prostate |
Pathology detail |
--- |
Optional |
zygosity |
Molecular test |
6142510 |
Optional |